Reading:Correction: Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China
Correction: Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China
Authors
Jing-Wei Li
Yu-Tao Guo
Gian Luca Di Tanna
Bruce Neal
Yun-Dai Chen
Aletta E. Schutte
Abstract
This article details a correction to: Li J-W, Guo Y-T, Di Tanna GL, Neal B, Chen Y-D, Schutte AE. Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China. Global Heart. 2021;16(1):47. DOI: http://doi.org/10.5334/gh.913.
The original article was published without complete funding details. It listed one funder, the National Natural Science Foundation of China (H2501), National Key Research and Development Project of China (2018YFC2001200).
There was another funder missing from the original article, the Chinese Military Health Care (20BJZ26).
The originally listed funder covered expenses for enrolment and follow-up of patients, and the purchase and maintenance of necessary equipment. The second funder covered the costs of publication.
J.L. held an International Postdoctoral Exchange Fellowship Program China (20170103) during the course of this work.
G. Tao has no disclosures.
A.E. Schutte received speaker honoraria from Omron Healthcare, Takeda Pharmaceuticals, Novartis, Servier, and serves on research advisory board for Abbott. She is President of the International Society of Hypertension, 2018–2020.
G.L. Di Tanna has no disclosures.
B. Neal is supported by an Australian National Health and Medical Research Council Principal Research Fellowship; holds a research grant for this study from Janssen; and has held research grants for other large-scale cardiovascular outcome trials from Roche, Servier, and Merck Schering Plough; and his institution has received consultancy, honoraria, or travel support for contributions he has made to advisory boards and/or the continuing medical education programs of Abbott, Janssen, Novartis, Pfizer, Roche, and Servier.
